1785-PUB: Dyslipidemia Management in Patients with the First Acute Coronary Event—A Retrospective Observational EMR-Based RWE Study

Backgroud: The understanding of the current state of evidence-based lipid management after ACS is critical for improving outcomes after the first coronary event. The present study was conducted to evaluate the real-world prescribing patterns of statin therapy over one year in adults presenting with the first ACS event. Material & Methods: The data of 527 patients with the first event of ACS receiving Statins based therapy from 10 healthcare centers across India were considered for the analysis starting from January 2018 to December 2020. The various doses of Statins based therapy at the time of ACS event and at Visit 1 and at the end of 12 months and the percentage of patients who have achieved guideline LDL levels were analysed. Results: The most common statins used are Atorvastain 80mg & 40mg, Rosuvastatin 40mg OD. Dose of Atorvastatin & Rosuvastatin was reduced from High intensity to moderate intensity in 21.97% & 2.64% patients during visit 1. After 12 months, the dose of Atorvastatin was further reduced in 7.98% and 31.20% on Rosuvastatin. The desired LDL as per Indian & global guidelines of <30mg/dl, <55mg/dl, <70mg/dl, <100mg/dl is achieved in only 2.66%, 19.37%, 47.94%, 91.52% patients on statin based therapy respectively. Conclusion: The Doses of statins were reduced from High intensity to moderate/low intensity therapy despite patients were not achieving desired LDL levels as per Indian & Global guidelines. The present study emphasizes the use of right intensity statins in ACS patients to achieve desired cardiac outcomes. Disclosure J.Christopher: None. A.Gupta: None. B.Pakshirajan: None. B.P.Kotak: Employee; Dr. Reddy’s Laboratories Ltd. K.Gaurav: None. R.T.Rathod: None. M.Syed: None. V.C.Kanuru: None. A.T: None.